Kyntra Bio
KYNB
190 hedge funds and large institutions have $2.77B invested in Kyntra Bio in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 77 increasing their positions, 55 reducing their positions, and 52 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 55
0.13% more ownership
Funds ownership: 2.71% → 2.85% (+0.13%)
12% less capital invested
Capital invested by funds: $3.15B → $2.77B (-$385M)
14% less call options, than puts
Call options by funds: $23.8M | Put options by funds: $27.6M
16% less funds holding
Funds holding: 225 → 190 (-35)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
62% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$58.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$34.3M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$31.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$30.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$28.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$51.5M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$38.5M |
| 3 |
Jennison Associates
New York
|
-$28.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.8M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$12.2M |
KYNB Hedge Fund Activity: Q2 2019 in Review
190 of the 4,624 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2019, worth a combined $2.77B — down 12% from $3.15B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of KYNB and 20 opened new positions — a net loss of 32 holders — while 55 trimmed existing stakes and 77 added.
The largest buyer was EcoR1 Capital, adding an estimated $58.8M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $51.5M sold.
- 190 institutional investors held Kyntra Bio (KYNB) as of Q2 2019, down from 225 in Q1 2019.
- Funds reported $2.77B of Kyntra Bio stock for Q2 2019, down 12% quarter-over-quarter.
- 20 funds opened new Kyntra Bio positions in Q2 2019 and 52 closed out, a net change of -32 holders.
- The largest Kyntra Bio buyer in Q2 2019 was EcoR1 Capital, an estimated $58.8M added.
- The largest Kyntra Bio seller in Q2 2019 was Eagle Asset Management, an estimated $51.5M sold.
Based on aggregated 13F filings for Q2 2019.